What Happened?
Shares of healthcare tech company GoodRx (NASDAQ: GDRX) jumped 9.5% in the afternoon session after it announced it would provide access to Novo Nordisk's oral semaglutide medication, known as the Ozempic pill, for eligible self-pay patients with type 2 diabetes.
The prescription savings platform detailed that the popular diabetes treatment would be available starting at $149 per month for a 1.5mg dose through its nationwide pharmacy network, with higher dosages of 4mg and 9mg priced at $199 and $299 per month, respectively.
This move adds an oral option to the widely used Ozempic treatment, potentially broadening its accessibility for patients who prefer pills over injections. By offering competitive self-pay pricing for a high-demand medication, GoodRx is tapping into the growing market for this class of drugs.
Is now the time to buy GoodRx? Access our full analysis report here, it’s free.
What Is The Market Telling Us
GoodRx’s shares are extremely volatile and have had 37 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The previous big move we wrote about was 16 days ago when the stock gained 3.6% on the news that the company announced it now offers access to the new higher-dose Wegovy® HD (semaglutide) injection for self-pay patients at a price of $399 per month.
This move came amid a growing demand for GLP-1 treatments, a class of drugs that includes Wegovy. GoodRx's initiative simplified access to the popular medication by providing clear pricing that scaled with quantity.
A two-month supply was made available for $798, and a three-month supply for $1,197. The effort was seen as a way to provide consumers with flexibility and predictable costs, tapping into the significant self-pay market for these sought-after treatments.
GoodRx is down 6.7% since the beginning of the year, and at $2.57 per share, it is trading 49.9% below its 52-week high of $5.12 from August 2025. Investors who bought $1,000 worth of GoodRx’s shares 5 years ago would now be looking at only $66.02.
ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention.
AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice.
